Abstract

The present disclosure relates to multi-payload antibody conjugates and preparation methods thereof. The preparation methods utilize an enzymatic site-specific conjugation technology and mutually orthogonal reactions such that highly homogeneous multi-payload antibody conjugates could be produced. The present disclosure further provides antibody-drug conjugates (ADCs) targeting multiple antigens (e.g., TROP2, HER2, Nectin-4, etc.) and pharmaceutical compositions comprising said ADCs. Also described herein are methods of using the ADCs for treatment of diseases such as cancers.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 9/10 - Transferases (2.)

Abstract

The present disclosure relates to a glycan linker and a method for preparing a glycoengineered antibody conjugated with payloads. Also provided herein is an antibody conjugate prepared using the glycoengineered antibody and a preparation method thereof. The present disclosure further provides antibody-drug conjugates (ADCs) targeting several antigens (e.g., TROP2, HER2, Nectin-4, etc.) and pharmaceutical compositions comprising said ADCs. Also described herein are methods of using the ADCs for treatment of diseases such as cancers.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C12P 21/00 - Preparation of peptides or proteins
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Goods & Services

immunostimulants; chemico-pharmaceutical preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; enzymes for medical purposes; biological preparations for medical purposes; pharmaceutical preparations; vaccines; drugs for medical purposes; hormones for medical purposes; adjuvants for medical purposes; medicines for human purposes; ferments for pharmaceutical purposes; enzyme preparations for medical purposes; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; Anti-cancer drugs; Anticancer preparations; Compounds for treating cancer.

Goods & Services

Immunostimulants; Chemical reagents for medical or veterinary purposes; Enzymes for medical purposes; Vaccines; Hormones for medical purposes; Adjuvants for medical purposes; Ferments for pharmaceutical purposes; Enzyme preparations for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Tumor suppressing agents; Pharmaceutical preparations for suppressing tumors; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for use in chemotherapy; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Pharmaceutical preparations for the treatment and prevention of cancer to be treated; Preparations of microorganisms for medical purposes

Goods & Services

(1) Anti-cancer preparations; biological preparations made from human blood cells for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals to treat cancer; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents

Abstract

The present invention provides an antibody or an antigen-binding portion thereof that binds to Nectin-4. Also provided is an antibody-drug conjugate (ADC) including a drug moiety conjugated to the anti-Nectin-4 antibody or antigen-binding portion thereof. Also disclosed are methods of using the antibody or ADC for inhibiting cancer cell proliferation.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure provides linker-payload conjugates including a bioorthogonal group and a hydrophilic moiety. The improved linker-payloads for antibody conjugation and improved antibody drug conjugates (ADCs) exhibit greater stability in blood circulation and enhanced drug delivery and drug release efficiencies in target cells. The present disclosure also relates to antibodies and antigen-binding fragments thereof targeting TROP2, as well as pharmaceutical compositions including TROP2 ADCs. Also described herein are methods of using TROP2 ADCs for treatment of subjects associated with pathological conditions.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 38/06 - Tripeptides
• A61K 38/07 - Tetrapeptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
• C07K 5/037 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link the abnormal link being formed by the side chain of an alpha-amino acid, e.g. gamma-Glu, epsilon-Lys, glutathione
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to novel glycosynthase enzymes for antibody or antibody-drug conjugates (ADCs) engineering. The enzyme mutants, termed EndoSc-D233Q/E350N and EndoSc-D233Q/E350Q, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSc-D233Q/E350N and EndoSc- D233Q/E350Q can be applied to various mAbs targeting different receptors. It has been found that both mAb-GlcNAc and mAb-GlucNAc(Fuc) were suitable substrates for both EndoSc mutants.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12P 21/00 - Preparation of peptides or proteins
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides linker-payload conjugates including a cysteine-reactive group and a hydrophilic moiety. The improved linker-payloads for biomolecules conjugation and improved drug conjugates exhibit greater stability in blood circulation and enhanced drug delivery and drug release efficiencies in target cells. The present disclosure also relates to antibodies and antigen-binding fragments thereof for several antigen targets (e.g. cMET, HER3, EGFR, TROP2, HER2, Nectin-4, etc.), as well as pharmaceutical compositions including ADCs. Also described herein are methods of using ADCs for treatment of subjects associated with pathological conditions.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

Methods and reagents suitable for in vitro diagnostic assay comprising a qualitative immunohistochemical assay using anti-Globo H antibodies and/or binding fragments thereof are provided. The method comprises the detection of Globo-H expression levels in formalin-fixed, paraffin-embedded (FFPE) cancer tissue using a visualization system. The Globo-H expression can be determined by using tumor scoring showing partial or complete staining at any intensity.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The present disclosure relates to treating cancer patients with anti-dendritic cells (anti-DCs)/anti-immunogenic cell death (anti-ICD) bispecific engager combined with tumor ICD inducers to enhance the dendritic cell activity. Exemplary polyvalent proteins include at least one DC binding site and at least one ICD binding site. In certain embodiments, the binding sites may be linked through a constant immunoglobulin region. Anti-DC and anti-ICD monoclonal antibodies are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present disclosure provides synthesis methods used in the preparation of an acyl chain of QS-21 and its derivative.

IPC Classes  ?

• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07C 45/56 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds from heterocyclic compounds
• C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
• C07D 263/24 - Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
• C07D 339/08 - Six-membered rings
• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 7/06 - Heterocyclic radicals

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• G01N 30/02 - Column chromatography

Abstract

The present disclosure relates to a method for enhancing the quality (DAR distribution, stability and etc.) of glycosylated antibody-drug conjugates (ADCs) using active charcoal. In particular, the present disclosure adopts hydrophobic interaction chromatography (HIC) column, Protein A chromatography, active charcoal stirs and buffer exchange either alone or in tandem in order to exclude free glycosynthase enzymes. Therefore, the purity of glycosylated ADCs could be raised and ADC degradation could be prevented. Finally, the quality of OBI-902 (anti-TROP2 ADC) and OBI-904 (anti-Nectin-4 ADC) drug substance (DS) can be further determined.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• G01N 30/02 - Column chromatography

Goods & Services

(1) Chemical analysis; chemical research; medical research; medical research services; pharmaceutical research and development; scientific research in the field of genetics; scientific laboratory services; scientific research; biological research; medical research services in the field of cancer; medical and scientific research in the field of cancer treatment and diagnosis; providing laboratory research services in the field of gene expression, namely, cancer biology; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; providing information about medical research in the field of cancer, oncology; medical research in the field of oncology; chemical research services; scientific research and development; chemical research and analysis; biological research and analysis; technical research in the field of pharmaceutical studies;

Goods & Services

Immunostimulants; Chemical reagents for medical or veterinary purposes; Enzymes for medical purposes; Vaccines; Hormones for medical purposes; Adjuvants for medical purposes; Ferments for pharmaceutical purposes; Enzyme preparations for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Tumor suppressing agents; Pharmaceutical preparations for suppressing tumors; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for use in chemotherapy; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Pharmaceutical preparations for the treatment and prevention of cancer to be treated; Preparations of microorganisms for medical purposes

Goods & Services

(1) Anti-cancer preparations; biological preparations made from human blood cells for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents

Goods & Services

Scientific laboratory services; Scientific research; Chemical analysis; Chemical research; Scientific research in the field of genetics; Biological research; Medical research; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Providing information about medical research in the field of cancer, oncology; Medical research in the field of oncology; Chemical research services; Medical research services; Scientific research and development; Pharmaceutical research and development; Chemical research and analysis; Biological research and analysis; Technical research in the field of pharmaceutical studies

Goods & Services

Immunostimulants; chemico-pharmaceutical preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; enzymes for medical purposes; biological preparations for medical purposes; pharmaceutical preparations; vaccines; drugs for medical purposes; hormones for medical purposes; adjuvants for medical purposes; medicines for human purposes; ferments for pharmaceutical purposes; enzyme preparations for medical purposes; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; Anti-cancer drugs; Anticancer preparations; Compounds for treating cancer.

Goods & Services

Technological research; conducting technical project studies; scientific laboratory services; scientific research; chemistry services; chemical analysis; chemical research; scientific research in the field of genetics; clinical trials; biological research; medical research; bacteriological research; culturing of cells for scientific research purposes; research and development of new products for others; quality control; research in the field of artificial intelligence technology; technical writing; research in the field of excavation; Scientific research for medical purposes in the area of cancerous diseases; Medical research in the field of oncology.

Abstract

The present disclosure relates to treating cancer patients with anti-dendritic cells (anti-DCs)/anti-immunogenic cell death (anti-ICD) bispecific engager combined with tumor ICD inducers to enhance the dendritic cell activity. Exemplary polyvalent proteins include at least one DC binding site and at least one ICD binding site. In certain embodiments, the binding sites may be linked through a constant immunoglobulin region. Anti-DC and anti-ICD monoclonal antibodies are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants

Goods & Services

(1) Anti-cancer preparations; biological preparations made from human blood cells for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents (1) Chemical analysis; chemical research; medical research; medical research services; pharmaceutical research and development; scientific research in the field of genetics (2) Biological therapeutic research services; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Providing information about medical research in the field of cancer, oncology; Medical research in the field of oncology; Chemical research services; Chemical research and analysis; biochemical research and analysis; Technical research in the field of pharmaceutical studies;

Goods & Services

Scientific laboratory services; Scientific research; Chemical analysis; Chemical research; Scientific research in the field of genetics; Biological research; Medical research; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Providing information about medical research in the field of cancer, oncology; Medical research in the field of oncology; Chemical research services; Medical research services; Scientific research and development; Pharmaceutical research and development; Chemical research and analysis; Biological research and analysis; Technical research in the field of pharmaceutical studies

Goods & Services

Immunostimulants; Chemical reagents for medical or veterinary purposes; Enzymes for medical purposes; Vaccines; Hormones for medical purposes; Adjuvants for medical purposes; Ferments for pharmaceutical purposes; Enzyme preparations for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Tumor suppressing agents; Pharmaceutical preparations for suppressing tumors; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for use in chemotherapy; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Pharmaceutical preparations for the treatment and prevention of cancer to be treated; Preparations of microorganisms for medical purposes

Goods & Services

Immunostimulants; chemico-pharmaceutical preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; enzymes for medical purposes; biological preparations for medical purposes; pharmaceutical preparations; vaccines; drugs for medical purposes; hormones for medical purposes; adjuvants for medical purposes; medicines for human purposes; ferments for pharmaceutical purposes; enzyme preparations for medical purposes; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; Anti-cancer drugs; Anticancer preparations; Compounds for treating cancer. Technological research; conducting technical project studies; scientific laboratory services; scientific research; chemistry services; chemical analysis; chemical research; scientific research in the field of genetics; clinical trials; biological research; medical research; bacteriological research; culturing of cells for scientific research purposes; research and development of new products for others; quality control; research in the field of artificial intelligence technology; technical writing; research in the field of excavation; Scientific research for medical purposes in the area of cancerous diseases; Medical research in the field of oncology.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 38/07 - Tetrapeptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
• C07K 5/037 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link the abnormal link being formed by the side chain of an alpha-amino acid, e.g. gamma-Glu, epsilon-Lys, glutathione

Abstract

The present disclosure provides linker-payload conjugates including a bioorthogonal group and a hydrophilic moiety. The improved linker-payloads for antibody conjugation and improved antibody drug conjugates (ADCs) exhibit greater stability in blood circulation and enhanced drug delivery and drug release efficiencies in target cells. The present disclosure also relates to antibodies and antigen-binding fragments thereof for several antigen targets (e.g. TROP2, HER2, Nectin-4, etc.), as well as pharmaceutical compositions including ADCs. Also described herein are methods of using ADCs for treatment of subjects associated with pathological conditions.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 38/07 - Tetrapeptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
• C07K 5/037 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link the abnormal link being formed by the side chain of an alpha-amino acid, e.g. gamma-Glu, epsilon-Lys, glutathione
• A61P 35/00 - Antineoplastic agents

Goods & Services

(1) Anti-cancer preparations; biological preparations made from human blood cells for the treatment of cancer; biological preparations made from living tissues for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents

Goods & Services

Chemical reagents for medical or veterinary purposes; Vaccines; Anti-cancer preparations; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Tumor suppressing agents; Pharmaceutical preparations for suppressing tumors; Medicinal preparations for use in oncology; Pharmaceutical preparations for use in chemotherapy; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Pharmaceutical preparations for the treatment and prevention of cancer to be treated

Goods & Services

Immunostimulants; chemico-pharmaceutical preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; enzymes for medical purposes; biological preparations for medical purposes; pharmaceutical preparations; vaccines; drugs for medical purposes; hormones for medical purposes; adjuvants for medical purposes; medicines for human purposes; ferments for pharmaceutical purposes; enzyme preparations for medical purposes; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; Anti-cancer drugs; Anticancer preparations; Compounds for treating cancer.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

Antibody drug conjugate (ADC) comprising a drug moiety conjugated to antibody or antigen binding fragments thereof that bind to TROP2 disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The ADC of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the ADC disclosed herein can include carcinomas, such as lung cancer, breast cancer, head-and-neck cancer, esophagus cancer, stomach cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervix cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer and oral cancer.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are the use of the compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate, or a pharmaceutically acceptable salt, isotopic variant or solvate thereof in the manufacture of a medicament for treating cancer, and a composition which comprises the above compound and at least one anti-cancer drug.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61P 35/00 - Antineoplastic agents

Abstract

A pharmaceutical composition, including a compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-N ethyl-N,N′-bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present disclosure relates to novel glycosynthase enzymes for antibody-drug conjugates (ADCs) engineering. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Peijeta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb- GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides antibody or the antigen-binding portion thereof bind to carbohydrate antigen, such as Globo series antigens (e.g. Globo H, SSEA-4 or SSEA-3). Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to chimeric antigen receptors (CARs), which bind to Globo series antigens (e.g. Globo H, SSEA-3 or SSEA-4), including an antigen-binding fragment (Fab) or a single-chain variable fragment (scFv). Further, the present methods are also provided for administering CARs to a subject in an amount effective to inhibit cancer cells.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Goods & Services

(1) Anti-cancer preparations; biological preparations for treating tumors; biological preparations made from human blood cells for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents

Goods & Services

Carbide; Cellulose; Glycogen; Glycoprotein; Sulfides; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Adjuvants, other than for medical or veterinary purposes; Antioxidants for use in the manufacture of pharmaceuticals; Biochemical catalysts; Biological preparations for use in industry and science; Carbonic hydrates; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Fatty acids for use in pharmaceutical; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Protein in raw material form for scientific and medical research; Proteins for use in manufacture; Proteins for use in the manufacture of drugs Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents Biological research; Biological research and analysis; Chemical analysis; Chemical research; Chemical research and analysis; Chemical research services; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research; Medical research in the field of oncology; Medical research services; Medical research services in the field of cancer; Pharmaceutical research and development; Providing information about medical research in the field of cancer, oncology; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research in the field of genetics; Technical research in the field of pharmaceutical studies Administering vaccines to patients; Alternative medicine services; Cancer screening services; Cultured cell bank services for medical transplantation; Health care; Health care services for treating cancer; Health assessment services; Health counselling; Human tissue bank services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical assistance; Medical screening; Medical treatment using cultured cells; Nursing, medical; Occupational therapy; Providing health information in the field of cancer prevention and treatment; Providing information in the field of cancer prevention, screening, diagnosis and treatment; Regenerative medicine services; Remote monitoring of medical data for medical diagnosis and treatment; Telemedicine services

Goods & Services

Proteins for use in manufacture; glucosides; carbonic hydrates; ferments for chemical purposes; biochemical catalysts; protein [raw material]; fatty acids; cellulose derivatives [chemicals]; lactose [raw material]; animal albumen [raw material]; carbide; sulfides; adjuvants, other than for medical or veterinary purposes; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes; bacteriological preparations, other than for medical and veterinary use; chlorides; Active chemical ingredients for use in the manufacture of anti-cancer drugs. Immunostimulants; chemico-pharmaceutical preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; enzymes for medical purposes; biological preparations for medical purposes; pharmaceutical preparations; vaccines; drugs for medical purposes; hormones for medical purposes; adjuvants for medical purposes; medicines for human purposes; ferments for pharmaceutical purposes; enzyme preparations for medical purposes; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; Anti-cancer drugs; Anticancer preparations; Compounds for treating cancer. Technological research; conducting technical project studies; scientific laboratory services; scientific research; chemistry services; chemical analysis; chemical research; scientific research in the field of genetics; clinical trials; biological research; medical research; bacteriological research; culturing of cells for scientific research purposes; research and development of new products for others; quality control; research in the field of artificial intelligence technology; technical writing; research in the field of excavation; Scientific research for medical purposes in the area of cancerous diseases; Medical research in the field of oncology. Medical screening; vaccination services; alternative medicine services; human tissue bank services; occupational therapy; nursing, medical; regenerative medicine services; medical clinic services; medical assistance; medical treatment using cultured cells; cultured cell bank services for medical transplantation; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; telemedicine services; therapy services; pharmacy advice; remote monitoring of medical data for medical diagnosis and treatment; Medical services in the field of oncology; Providing on-line information relating to oncology; Cervical cancer screening services; Bowel cancer screening services.

Abstract

A method against snake envenomation includes administering to a subject in need thereof a pharmaceutical composition containing a flavonoid compound. The flavonoid compound is selected from the group consisting of isorhamnetin, quercetin, and a combination thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 39/02 - Antidotes

Goods & Services

(1) Anti-cancer preparations; biological preparations for treating tumors; biological preparations made from human blood cells for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents

Goods & Services

Proteins for use in manufacture; glucosides; carbonic hydrates; ferments for chemical purposes; biochemical catalysts; protein [raw material]; fatty acids; cellulose derivatives [chemicals]; lactose [raw material]; animal albumen [raw material]; carbide; sulfides; adjuvants, other than for medical or veterinary purposes; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes; bacteriological preparations, other than for medical and veterinary use; chlorides; Active chemical ingredients for use in the manufacture of anti-cancer drugs. Immunostimulants; chemico-pharmaceutical preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; enzymes for medical purposes; biological preparations for medical purposes; pharmaceutical preparations; vaccines; drugs for medical purposes; hormones for medical purposes; adjuvants for medical purposes; medicines for human purposes; ferments for pharmaceutical purposes; enzyme preparations for medical purposes; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; Anti-cancer drugs; Anticancer preparations; Compounds for treating cancer. Technological research; conducting technical project studies; scientific laboratory services; scientific research; chemistry services; chemical analysis; chemical research; scientific research in the field of genetics; clinical trials; biological research; medical research; bacteriological research; culturing of cells for scientific research purposes; research and development of new products for others; quality control; research in the field of artificial intelligence technology; technical writing; research in the field of excavation; Scientific research for medical purposes in the area of cancerous diseases; Medical research in the field of oncology. Medical screening; vaccination services; alternative medicine services; human tissue bank services; occupational therapy; nursing, medical; regenerative medicine services; medical clinic services; medical assistance; medical treatment using cultured cells; cultured cell bank services for medical transplantation; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; telemedicine services; therapy services; pharmacy advice; remote monitoring of medical data for medical diagnosis and treatment; Medical services in the field of oncology; Providing on-line information relating to oncology; Cervical cancer screening services; Bowel cancer screening services.

Goods & Services

Immunostimulants; chemico-pharmaceutical preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; enzymes for medical purposes; biological preparations for medical purposes; pharmaceutical preparations; vaccines; drugs for medical purposes; hormones for medical purposes; adjuvants for medical purposes; medicines for human purposes; ferments for pharmaceutical purposes; enzyme preparations for medical purposes; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; Anti-cancer drugs; Anticancer preparations; Compounds for treating cancer.

Goods & Services

Carbide; Cellulose; Glycogen; Glycoprotein; Sulfides; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Adjuvants, other than for medical or veterinary purposes; Antioxidants for use in the manufacture of pharmaceuticals; Biochemical catalysts; Biological preparations for use in industry and science; Carbonic hydrates; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Fatty acids for use in pharmaceutical; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Protein in raw material form for scientific and medical research; Proteins for use in manufacture; Proteins for use in the manufacture of drugs Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents Biological research; Biological research and analysis; Chemical analysis; Chemical research; Chemical research and analysis; Chemical research services; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research; Medical research in the field of oncology; Medical research services; Medical research services in the field of cancer; Pharmaceutical research and development; Providing information about medical research in the field of cancer, oncology; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research in the field of genetics; Technical research in the field of pharmaceutical studies Administering vaccines to patients; Alternative medicine services; Cancer screening services; Cultured cell bank services for medical transplantation; Health care; Health care services for treating cancer; Health assessment services; Health counselling; Human tissue bank services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical assistance; Medical screening; Medical treatment using cultured cells; Nursing, medical; Occupational therapy; Providing health information in the field of cancer prevention and treatment; Providing information in the field of cancer prevention, screening, diagnosis and treatment; Regenerative medicine services; Remote monitoring of medical data for medical diagnosis and treatment; Telemedicine services

Goods & Services

(1) Anti-cancer preparations; biological preparations for treating tumors; biological preparations made from human blood cells for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents

Goods & Services

Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents

Goods & Services

(1) Anti-cancer preparations; biological preparations for treating tumors; biological preparations made from human blood cells for the treatment of cancer; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceuticals for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; tumor suppressing agents

Abstract

The present disclosure provides synthesis methods used in the preparation of an acyl chain of QS-21and its derivative.

IPC Classes  ?

• C07C 29/09 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
• C07C 69/52 - Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
• C07C 29/36 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy groups, e.g. O-metal
• C07B 53/00 - Asymmetric syntheses
• C07H 1/00 - Processes for the preparation of sugar derivatives

Abstract

Here we developed a COVID-19 vaccine using delta strain spike protein as the antigen to provide a more comprehensive protection against delta strain, and possibly certain degree of protection against other known variants. In combination with a saponin based ISCOM (immune stimulating complex) adjuvant in nanoparticle format, which provides better immunogenicity towards T cell responses than traditional Q.S-21. The vaccine candidate that shows the best immunogenicity would be further developed to enter clinical trial.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/12 - Viral antigens
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A stable AST-3424 injection preparation, being a solution containing 0.1-200 mg/ml or 1-200 mg/ml of AST-3424 active pharmaceutical ingredient. A solvent in the solution contains a C2-C8 monohydric alcohol. The preparation method comprises the following steps: subjecting the AST-3424 active pharmaceutical ingredient and a partial prescription volume of ethanol to a first dissolution and formulation; adding a prescription volume of propylene glycol for a second dissolution and formulation; and then adding the remaining prescription volume of ethanol for mixing and dissolving to obtain a solution containing 1-200 mg/ml of AST-3424 active pharmaceutical ingredient. Provided is an AST-3424 injection for injection, wherein the solvent is water, a glucose solution, ethanol, or propylene glycol, the solutes consist of the AST-3424 active pharmaceutical ingredient, an isotonic regulator, and a pH regulator. The concentration of the AST-3424 active pharmaceutical ingredient of the injection is 0.001-1.000 mg/ml, the pH of the injection is 6.8-10.5, and the solution is an isotonic solution.

IPC Classes  ?

• A61K 31/67 - Phosphorus compounds having sulfur as a ring hetero atom
• A61J 1/06 - Ampoules or cartridges
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
• A61K 9/08 - Solutions
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

Abstract

The present disclosure relates to treating cancer patients with anti-dendritic cells (anti-DCs)/anti-immunogenic cell death (anti-ICD) bispecific engager combined with tumor ICD inducers to enhance the dendritic cell activity. Exemplary polyvalent proteins include at least one DC binding site and at least one ICD binding site. In certain embodiments, the binding sites may be linked through a constant immunoglobulin region. Anti-DC and anti-ICD monoclonal antibodies are also provided.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides antibodies or the antigen-binding portion thereof, that bind to stage-specific embryonic antigen 3 (SSEA-3) antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions include an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 35/00 - Antineoplastic agents

Abstract

A pharmaceutical composition, including a compound l-(3-(3-N,N- dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-l-ethyl-N,N'- bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.

IPC Classes  ?

• A61K 31/664 - Amides of phosphorus acids
• A61P 35/00 - Antineoplastic agents

Abstract

A pharmaceutical composition, including a compound l-(3-(3-N,N- dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-l-ethyl-N,N'- bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.

IPC Classes  ?

• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• C07D 203/22 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
• C07F 9/02 - Phosphorus compounds

Abstract

Provided are the use of the compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-ethyl-N,N'-bis(ethylene)phosphoramidate, or a pharmaceutically acceptable salt, isotopic variant or solvate thereof in the manufacture of a medicament for treating cancer, and a composition which comprises the above compound and at least one anti-cancer drug.

IPC Classes  ?

• A61K 31/04 - Nitro compounds
• A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
• A61K 31/664 - Amides of phosphorus acids
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are the use of the compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-ethyl-N,N'-bis(ethylene)phosphoramidate, or a pharmaceutically acceptable salt, isotopic variant or solvate thereof in the manufacture of a medicament for treating cancer, and a composition which comprises the above compound and at least one anti-cancer drug.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 31/04 - Nitro compounds
• A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
• A61K 31/664 - Amides of phosphorus acids

Abstract

The present disclosure relates to chimeric antigen receptors (CARs), which bind to Globo series antigens (e.g. Globo H, SSEA-3 or SSEA-4), including an antigen-binding fragment (Fab) or a single-chain variable fragment (scFv). Further, the present methods are also provided for administering CARs to a subject in an amount effective to inhibit cancer cells.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides antibody or the antigen-binding portion thereof bind to carbohydrate antigen, such as Globo series antigens (e.g. Globo H, SSEA-4 or SSEA-3). Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-form” compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-form” compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

IPC Classes  ?

• C07F 9/24 - Esteramides
• C07C 231/14 - Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups

Abstract

The present invention relates to a method for predicting human immune response to therapeutic cancer vaccine. This method includes a series of culturing procedures and a modified ELISPOT assay to detect total antibody, antigen specific antibody, and cytokine induction ability from human individual's PBMC.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a botulinum toxin type A complex, and a formulation thereof and a usage method therefor. The present invention provides the botulinum toxin type A complex, comprising an HA70 component, an HA17 component, an HA33 component, an NTNH component, and a BoNT/A1 component, wherein the botulinum toxin complex has a molecular weight of 740-790kDa. Compared with the existing botulinum toxin complexes, the botulinum toxin complex of the present invention is smaller in molecular weight and higher in safety, and has a comparable treatment effect.

IPC Classes  ?

• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides antibodies or the antigen-binding portion thereof, that bind to stage-specific embryonic antigen 3 (SSEA-3) antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions include an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 5/12 - Fused cells, e.g. hybridomas

Abstract

Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 49/00 - Preparations for testing in vivo
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure is related to the six isomer structures (OBI-821-1990-V1A, OBI-821-1990-V1B, OBI-821-1990-V2A, OBI-821-1990-V2B, OBI-821-1858-A, and OBI-821-1858-B) of isolated OBI-821 adjuvant and the method for evaluating the quality thereof. The method of the present disclosure adopts hydrophilic interaction liquid chromatography (HILIC) and reverse phase high performance liquid chromatography (RP-HPLC) either alone or in tandem and is able to separate the isomers of OBI-821 adjuvant in the consequent chromatography. Accordingly, the quality of OBI-821 adjuvant can be further evaluated.

IPC Classes  ?

• C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• G01N 30/14 - Preparation by elimination of some components
• G01N 30/60 - Construction of the column
• G01N 30/74 - Optical detectors
• G01N 30/86 - Signal analysis
• G01N 33/15 - Medicinal preparations
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• G01N 30/02 - Column chromatography

Abstract

Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

IPC Classes  ?

• C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents
• C07D 239/94 - Nitrogen atoms
• C07D 487/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
• C07H 19/06 - Pyrimidine radicals
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

A stable AST-3424 injection preparation, being a solution containing 0.1-200 mg/ml or 1-200 mg/ml of AST-3424 active ingredients. A solvent in the solution contains a C2-C8 monohydric alcohol. The preparation method comprises the following steps: performing first dissolution preparation on the AST-3424 active ingredients and a partial prescription amount of ethanol; adding a prescription amount of propylene glycol for the second-time dissolution preparation; and then, adding the remaining prescription amount of ethanol for mixing and dissolving to obtain a solution containing 1-200 mg/ml of AST-3424 active ingredients. The solvent of the AST-3424 injection is water, or a glucose solution, ethanol, and a propylene glycol solute consist of the AST-3424 active ingredients, an isotonic regulator, and a pH regulator. The concentration of the AST-3424 active ingredients of the injection is 0.001-1.000 mg/ml, the pH of the injection is 6.8-10.5, and the solution is an isotonic solution.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 35/00 - Antineoplastic agents

Abstract

Methods and reagents suitable for in vitro diagnostic assay comprising a qualitative immunohistochemical assay using anti-Globo H antibodies and/or binding fragments thereof are provided. The method comprises the detection of Globo-H expression levels in formalin-fixed, paraffin-embedded (FFPE) cancer tissue using a visualization system. The Globo-H expression can be determined by using tumor scoring showing partial or complete staining at any intensity.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The "R-form" compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity, After then, the "S-form" compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

IPC Classes  ?

• C07B 41/02 - Formation or introduction of functional groups containing oxygen of hydroxy or O-metal groups
• C07B 57/00 - Separation of optically-active organic compounds
• C12P 7/02 - Preparation of oxygen-containing organic compounds containing a hydroxy group

Abstract

A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The "R-form" compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity, After then, the "S-form" compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

IPC Classes  ?

• C07B 41/02 - Formation or introduction of functional groups containing oxygen of hydroxy or O-metal groups
• C07B 57/00 - Separation of optically-active organic compounds
• C12P 7/02 - Preparation of oxygen-containing organic compounds containing a hydroxy group

Abstract

The present disclosure is generally directed to treatment methods and compositions comprising administering anti-SSEA-4 antibodies; alone or in additive and/or synergistic combination with other therapeutic agents in oncology to enhance therapeutic efficacy whereby the interaction alters the epitope binding of Siglec-9 protein; including human Siglec-9 or a mammalian Siglec-9; wherein the use of such anti-SSEA-4 compositions are efficacious in preventing, reducing risk, or treating an individual with cancer.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07H 15/24 - Condensed ring systems having three or more rings
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and/or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perj eta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• G01N 30/02 - Column chromatography
• G01N 30/38 - Flow patterns

Abstract

The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 35/00 - Antineoplastic agents
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and/or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, S SEA-4, S SEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perjeta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

The present disclosure relates to treatment of cancer patients with anti-Globo series antigens (Globo H and S SEA-4) antibodies in combination with anti -negative immune check point antibody to rescue the inhibited T cell activity.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof

Abstract

The present invention relates to a method for predicting human immune response to therapeutic cancer vaccine. This method includes a series of culturing procedures and a modified ELISPOT assay to detect total antibody, antigen specific antibody, and cytokine induction ability from human individual's PBMC.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/548 - Carbohydrates, e.g. dextran

Abstract

The present disclosure is related to the six isomer structures (OBI-821-1990-V1A, OBI-821-1990-V1B, OBI-821-1990-V2A, OBI-821-1990-V2B, OBI-821-1858-A, and OBI-821-1858-B) of isolated OBI-821 adjuvant and the method for evaluating the quality thereof. The method of the present disclosure adopts hydrophilic interaction liquid chromatography (HILIC) and reverse phase high performance liquid chromatography (RP-HPLC) either alone or in tandem and is able to separate the isomers of OBI-821 adjuvant in the consequent chromatography. Accordingly, the quality of OBI-821 adjuvant can be further evaluated.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

IPC Classes  ?

• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• C07F 9/24 - Esteramides
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a method for producing CRM197 recombinant protein in cells. The method comprises culturing a cell comprising an expression plasmid with a polynucleotide and inducing expression of the CRM197 protein.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)

Abstract

The present disclosure is related to a method and composition for treating leukemia. The method comprises administering subject in need with an effective amount of a compound named OBI-3424 or OBI-3423. It shows particular efficacy in treating acute lymphoblastic leukemia (ALL), including T-ALL and B-ALL.

IPC Classes  ?

• A61K 31/04 - Nitro compounds
• A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.

IPC Classes  ?

• C07D 203/22 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• G06F 16/951 - IndexingWeb crawling techniques
• G06F 16/954 - Navigation, e.g. using categorised browsing
• G01N 29/02 - Analysing fluids
• G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
• G06F 3/0484 - Interaction techniques based on graphical user interfaces [GUI] for the control of specific functions or operations, e.g. selecting or manipulating an object, an image or a displayed text element, setting a parameter value or selecting a range
• G06F 17/22 - Manipulating or registering by use of codes, e.g. in sequence of text characters
• H03H 9/02 - Networks comprising electromechanical or electro-acoustic elementsElectromechanical resonators Details
• H03H 9/10 - Mounting in enclosures
• H03H 9/25 - Constructional features of resonators using surface acoustic waves
• A61P 35/00 - Antineoplastic agents
• C07F 9/564 - Three-membered rings

Abstract

Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof

Abstract

The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 5/16 - Animal cells
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

IPC Classes  ?

• C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
• C07H 19/06 - Pyrimidine radicals
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents
• C07D 239/94 - Nitrogen atoms
• C07D 487/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

IPC Classes  ?

• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• C07F 9/24 - Esteramides
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valnet, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 "SSEA3" and Stage-specific embryonic antigen 4 "SSEA4"). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca